Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Eye · 2025

Tryptyr (acoltremon)

The FDA approved Tryptyr (acoltremon) on May 28, 2025 to treat the signs and symptoms of dry eye disease.
Brand name
Tryptyr
Generic name
acoltremon
FDA approval date
May 28, 2025
Approved use (FDA wording)
To treat the signs and symptoms of dry eye disease
Company
Alcon Labs Inc.
Application
NDA217370
Dosage form / route
SOLUTION/DROPS · OPHTHALMIC
Drug class (EPC)
TRPM8 Thermoreceptor Agonist [EPC]
Boxed warning on label
Not listed
Category on this site
Eye

Indications and usage, from the FDA label

TRYPTYR is indicated for the treatment of the signs and symptoms of dry eye disease. TRYPTYR is a TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.